AHA Coding Clinic® for ICD-9 - 2007 Issue 4; V Code Update
Bisphosphonates (Diphosphonates)
Effective October 1, 2007, new E codes have been created to identify the adverse effects in therapeutic use of oral and intravenous bisphosphonates. Bisphosphonates (also diphosphonates) is a class of drugs that inhibits the resorption of bone. They are used in the prevention and treatment of Paget’s disease of the bone, osteoporosis, metastatic bone cancer, multiple myeloma and other conditions that involve fragile bones. They may also be used to reduce a raised calcium level in the blood or to treat osteoporosis. The most common side effects are nausea, abdominal pain and loose bowel movements. There...
Subscribe or sign in to view the full article.
Article Overview
This article explains a coding update related to bisphosphonates, a drug class used in several bone and calcium-related conditions, and notes the addition of diagnosis codes for adverse effects in therapeutic use. It is intended for coders and other revenue cycle professionals who need to understand the scope of the update, the affected code family, and the general clinical context without relying on the premium article for full details.
Why This Topic Matters
Understanding this update helps ensure that adverse effects associated with therapeutic bisphosphonate use are categorized consistently in claims and records. It is relevant for accurate diagnosis coding in settings where these drugs are commonly used.
Article Sections
-
Overview of bisphosphonates
Introduces the drug class and summarizes broad clinical contexts in which it is used.
-
Adverse effects and clinical context
Describes general side effects and other broad safety considerations associated with the medication class.
-
Drugs, Medicinal and Biological Substances Causing Adverse Effects in Therapeutic Use
Places the topic within a diagnosis-code category update and identifies the affected code family.
What You Will Learn
- The general purpose of the bisphosphonate coding update
- The broad clinical settings in which bisphosphonates are used
- The type of diagnosis-code family affected by the update
- The effective date associated with the change
Who Should Read This
- Medical coders
- Coding auditors
- Billing staff
- Revenue cycle professionals
- Clinical documentation teams
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com